
Hisakazu Ohtani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4354070/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant. European Journal of Clinical Pharmacology, 2022, 78, 613-621.	0.8	3
2	Inhibitory Effects of Cranberry Juice and Its Components on Intestinal OATP1A2 and OATP2B1: Identification of Avicularin as a Novel Inhibitor. Journal of Agricultural and Food Chemistry, 2022, 70, 3310-3320.	2.4	9
3	Comparison of the inhibitory properties of the fruit component naringenin and its glycosides against OATP1A2 genetic variants. Drug Metabolism and Pharmacokinetics, 2022, 46, 100464.	1.1	4
4	Relative contributions of metabolic enzymes toÂsystemic elimination can be estimated from clinical DDI studies: Validation using an in silico approach. International Journal of Clinical Pharmacology and Therapeutics, 2021, 59, 231-238.	0.3	2
5	Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: AÂcaseÂreport. International Journal of Clinical Pharmacology and Therapeutics, 2021, 59, 328-332.	0.3	3
6	Estimation of absolute oral bioavailability without performing an intravenous clinical study. Drug Metabolism and Pharmacokinetics, 2021, 38, 100392.	1.1	0
7	Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. Drug Metabolism and Pharmacokinetics, 2021, 38, 100384.	1.1	9
8	Digoxin absorption decreased independently of P-gp activity in rats with irinotecan-induced gastrointestinal damage. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 24.	0.4	1
9	Dual kinetics of OATP2B1: Inhibitory potency and pH-dependence of OATP2B1 inhibitors. Drug Metabolism and Pharmacokinetics, 2021, 41, 100416.	1.1	6
10	Time-dependent inhibition of CYP3A4-mediated midazolam metabolism by macrolide antibiotics in CYP3A4 genetic variants: Comparison with testosterone metabolism. International Journal of Clinical Pharmacology and Therapeutics, 2021, 59, 745-752.	0.3	0
11	Analysis of inhibition kinetics of three beverage ingredients, bergamottin, dihydroxybergamottin and resveratrol, on CYP2C9 activity. Drug Metabolism and Pharmacokinetics, 2021, 42, 100429.	1.1	2
12	pH-dependent transport kinetics of the human organic anion-transporting polypeptide 1A2. Drug Metabolism and Pharmacokinetics, 2020, 35, 220-227.	1.1	16
13	Citrus Fruit-Derived Flavanone Glycoside Narirutin is a Novel Potent Inhibitor of Organic Anion-Transporting Polypeptides. Journal of Agricultural and Food Chemistry, 2020, 68, 14182-14191.	2.4	13
14	Novel method to estimate the appropriate dosing interval for activated charcoal to avoid interaction with other drugs. European Journal of Clinical Pharmacology, 2020, 76, 1529-1536.	0.8	0
15	Profile of the inhibitory effects of gefitinib on CYP2D6 variants in vitro. International Journal of Clinical Pharmacology and Therapeutics, 2020, 58, 539-542.	0.3	2
16	lrinotecanâ€induced gastrointestinal damage impairs the absorption of dabigatran etexilate. Biopharmaceutics and Drug Disposition, 2019, 40, 315-324.	1.1	6
17	Effects of food type on the extent of drug-drug interactions between activated charcoal and phenobarbital in rats. Drug Metabolism and Pharmacokinetics, 2019, 34, 287-291.	1.1	1
18	Inhibitory kinetics of fruit components on CYP2C19 activity. Drug Metabolism and Pharmacokinetics, 2019, 34, 181-186.	1.1	8

#	Article	IF	CITATIONS
19	The extent of drug-drug interaction between amlodipine and activated charcoal is attenuated by food intake in rats. Drug Metabolism and Pharmacokinetics, 2019, 34, 108-110.	1.1	1
20	Current Status of Unapproved Drug Transactions <i>via</i> Internet Auction in Japan. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2019, 45, 591-595.	0.0	0
21	5-Fluororacil–Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate. Journal of Pharmaceutical Sciences, 2018, 107, 1430-1433.	1.6	4
22	Food intake attenuates the drug interaction between new quinolones and aluminum. Journal of Pharmaceutical Health Care and Sciences, 2018, 4, 11.	0.4	7
23	Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin. Biopharmaceutics and Drug Disposition, 2017, 38, 420-425.	1.1	4
24	Development and evaluation of an overseas clinical rotation program for undergraduate pharmacy students in Japan. Currents in Pharmacy Teaching and Learning, 2017, 9, 452-459.	0.4	1
25	5â€Fluorouracil treatment alters the expression of intestinal transporters in rats. Biopharmaceutics and Drug Disposition, 2017, 38, 509-516.	1.1	8
26	Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline. Biological and Pharmaceutical Bulletin, 2017, 40, 1010-1020.	0.6	1
27	<i>In silico</i> evaluation of warfarin–bucolome therapy. Biopharmaceutics and Drug Disposition, 2016, 37, 233-242.	1.1	3
28	Variation in the inhibitory potency of terbinafine among genetic variants ofÂCYP2D6. Drug Metabolism and Pharmacokinetics, 2015, 30, 321-324.	1.1	4
29	Decrease in Ciprofloxacin Absorption by Polyvalent Metal Cations Is Not Fully Attributable to Chelation or Adsorption. Drug Metabolism and Pharmacokinetics, 2014, 29, 414-418.	1.1	7
30	Prediction of the extent and variation of grapefruit juice–drug interactions from the pharmacokinetic profile in the absence of grapefruit juice. Biopharmaceutics and Drug Disposition, 2014, 35, 373-381.	1.1	7
31	A proposal to Improve Pharmacy Training Based on the Problem of OTC Drug Training. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2014, 40, 117-123.	0.0	2
32	Characterization of Transplacental Transfer of Paroxetine in Perfused Human Placenta: Development of a Pharmacokinetic Model to Evaluate Tapered Dosing. Drug Metabolism and Disposition, 2013, 41, 2124-2132.	1.7	12
33	Effect of Aromatase Inhibitors on Bone Mineral Density in a Japanese Breast Cancer Population. Drug Metabolism and Pharmacokinetics, 2013, 28, 446-450.	1.1	2
34	Mechanism-based Inhibition Profiles of Erythromycin and Clarithromycin with Cytochrome P450 3A4 Genetic Variants. Drug Metabolism and Pharmacokinetics, 2013, 28, 411-415.	1.1	24
35	Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 374-382.	0.3	12
36	Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies. British Journal of Clinical Pharmacology, 2012, 73, 248-256.	1.1	16

#	Article	IF	CITATIONS
37	Toxicodynamic Analysis of Cardiac Effects Induced by Four Cholinesterase Inhibitors in Rats. Journal of Pharmacy and Pharmacology, 2011, 48, 935-939.	1.2	5
38	A Comparative Pharmacokinetic-Pharmacodynamic Study of the Electrocardiographic Effects of Epinastine and Terfenadine in Rats. Journal of Pharmacy and Pharmacology, 2011, 49, 458-462.	1.2	21
39	Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 642-650.	0.7	29
40	Bottomâ€up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharmaceutics and Drug Disposition, 2011, 32, 498-506.	1.1	7
41	Comparison of the Inhibitory Profiles of Itraconazole and Cimetidine in Cytochrome P450 3A4 Genetic Variants. Drug Metabolism and Disposition, 2011, 39, 724-728.	1.7	24
42	Inhibitory Effects of Herbal Extracts on Breast Cancer Resistance Protein (BCRP) and Structure-Inhibitory Potency Relationship of Isoflavonoids. Drug Metabolism and Pharmacokinetics, 2010, 25, 170-179.	1.1	50
43	Influence of Extracellular K+ Concentrations on Quinidine-induced K+ Current Inhibition in Rat Ventricular Myocytes. Journal of Pharmacy and Pharmacology, 2010, 52, 99-105.	1.2	13
44	In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation. Journal of Pharmacy and Pharmacology, 2010, 53, 643-651.	1.2	8
45	Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide. Journal of Pharmacy and Pharmacology, 2010, 55, 995-1002.	1.2	10
46	Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil. Journal of Pharmacy and Pharmacology, 2010, 54, 729-733.	1.2	17
47	Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier. Journal of Pharmacy and Pharmacology, 2010, 54, 1055-1063.	1.2	27
48	Inhibitory Effects of the Antihistamines Epinastine, Terfenadine, and Ebastine on Potassium Currents in Rat Ventricular Myocytes. Journal of Pharmacy and Pharmacology, 2010, 51, 1059-1063.	1.2	9
49	Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4â€. Journal of Pharmacy and Pharmacology, 2010, 58, 1499-1505.	1.2	25
50	Saturable Binding of Finasteride to Steroid 5α-reductase as Determinant of Nonlinear Pharmacokinetics. Drug Metabolism and Pharmacokinetics, 2010, 25, 208-213.	1.1	15
51	Transplacental Pharmacokinetics of Diclofenac in Perfused Human Placenta. Drug Metabolism and Disposition, 2009, 37, 962-968.	1.7	16
52	Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine–alprazolam interaction in patients with psychosomatic disease. European Journal of Clinical Pharmacology, 2009, 65, 699-704.	0.8	11
53	Coâ€administration of proton pump inhibitors delays elimination of plasma methotrexate in highâ€dose methotrexate therapy. British Journal of Clinical Pharmacology, 2009, 67, 44-49.	1.1	137
54	Inhibitory Effects of Herbal Extracts on the Activity of Human Sulfotransferase Isoform Sulfotransferase 1A3 (SULT1A3). Biological and Pharmaceutical Bulletin, 2009, 32, 105-109.	0.6	13

#	Article	IF	CITATIONS
55	Quantitative Comparison of the Convulsive activity of Combinations of Twelve Fluoroquinolones with Five Nonsteroidal Antiinflammatory Agents. Drug Metabolism and Pharmacokinetics, 2009, 24, 167-174.	1.1	14
56	The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium. Cancer Chemotherapy and Pharmacology, 2008, 62, 427-432.	1.1	12
57	Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. International Journal of Neuropsychopharmacology, 2008, 11, 261-267.	1.0	53
58	Influence of SLCO1B3 Gene Polymorphism on the Pharmacokinetics of Digoxin in Terminal Renal Failure. Drug Metabolism and Pharmacokinetics, 2008, 23, 406-411.	1.1	22
59	Effects of Uremic Serum and Uremic Toxins on Hepatic Uptake of Digoxin. Therapeutic Drug Monitoring, 2008, 30, 576-582.	1.0	32
60	Questionnaire Survey on Use and Perception of Green Leaf Squeeze and other Dietary Supplements Targeting Their Users. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2008, 34, 644-650.	0.0	6
61	Kinetic Analysis of the Transport of Salicylic Acid, a Nonsteroidal Anti-inflammatory Drug, across Human Placenta. Drug Metabolism and Disposition, 2007, 35, 772-778.	1.7	15
62	Possible Mechanisms for the Pharmacokinetic Interaction Between Phenytoin and Folinate in Rats. Therapeutic Drug Monitoring, 2007, 29, 404-411.	1.0	2
63	Effects of Dosing Interval on the Pharmacokinetic Interaction Between Oral Small Spherical Activated Charcoal and Amlodipine in Humans. Journal of Clinical Pharmacology, 2007, 47, 904-908.	1.0	11
64	Development of a Pharmacokinetic Model to Optimize the Dosage Regimen of TS-1, a Combination Preparation of Tegafur, Gimeracil and Oteracil Potassium. Drug Metabolism and Pharmacokinetics, 2007, 22, 162-168.	1.1	9
65	Effect of macrolide antibiotics on uptake of digoxin into rat liver. Biopharmaceutics and Drug Disposition, 2007, 28, 113-123.	1.1	9
66	Inhibitory effects of various beverages on human recombinant sulfotransferase isoforms SULT1A1 and SULT1A3. Biopharmaceutics and Drug Disposition, 2007, 28, 491-500.	1.1	46
67	Possible case of potentiation of the antiplatelet effect of cilostazol by grapefruit juice. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 457-459.	0.7	19
68	Assessment of ?1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory. British Journal of Clinical Pharmacology, 2007, 63, 394-403.	1.1	4
69	Piloerection induced by replacing fluvoxamine with milnacipran. British Journal of Clinical Pharmacology, 2007, 63, 665-671.	1.1	6
70	Effects of Various Methoxyflavones on Vincristine Uptake and Multidrug Resistance to Vincristine in P-gp-Overexpressing K562/ADM Cells. Pharmaceutical Research, 2007, 24, 1936-1943.	1.7	41
71	Polymorphisms and Linkage Disequilibrium of the OATP8 (OATP1B3) Gene in Japanese Subjects. Drug Metabolism and Pharmacokinetics, 2006, 21, 165-169.	1.1	41
72	Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. British Journal of Clinical Pharmacology, 2006, 61, 671-676.	1.1	21

#	Article	IF	CITATIONS
73	Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists. British Journal of Clinical Pharmacology, 2006, 62, 196-199.	1.1	17
74	THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR. Drug Metabolism and Disposition, 2006, 34, 800-806.	1.7	19
75	EFFECTS OF HERBAL EXTRACTS ON THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B. Drug Metabolism and Disposition, 2006, 34, 577-582.	1.7	118
76	Analysis of Problems in Order Entry Procedure and Operation of Computerized Physician Order Entry Systems Based on a Questionnaire Sent to Doctors. Iryo Yakugaku (Japanese Journal of Pharmaceutical) Tj ETQqO	0000orgBT /	Overlock 10
77	Receptor Occupancy-based Analysis of the Contributions of Various Receptors to Antipsychotics-induced Weight Gain and Diabetes Mellitus. Drug Metabolism and Pharmacokinetics, 2005, 20, 368-378.	1.1	157
78	Functional characterization of adenosine transport across the BBB in mice. International Journal of Pharmaceutics, 2005, 290, 37-44.	2.6	16
79	Inhibitory Effects of Various Beverages on Ritodrine Sulfation by Recombinant Human Sulfotransferase Isoforms SULT1A1 and SULT1A3. Pharmaceutical Research, 2005, 22, 1406-1410.	1.7	21
80	Pharmacokinetic-Pharmacodynamic Analysis of Antipsychotics-induced Extrapyramidal Symptoms based on Receptor Occupancy Theory Incorporating Endogenous Dopamine Release. Drug Metabolism and Pharmacokinetics, 2005, 20, 187-199.	1.1	29
81	PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR PRALMORELIN HYDROCHLORIDE IN RATS. Drug Metabolism and Disposition, 2005, 33, 1488-1494.	1.7	9
82	Functional Analysis of Organic Cation Transporter 3 Expressed in Human Placenta. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 888-895.	1.3	107
83	FUNCTIONAL INDUCTION AND DE-INDUCTION OF P-GLYCOPROTEIN BY ST. JOHN'S WORT AND ITS INGREDIENTS IN A HUMAN COLON ADENOCARCINOMA CELL LINE. Drug Metabolism and Disposition, 2005, 33, 547-554.	1.7	62
84	CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B. Drug Metabolism and Disposition, 2005, 33, 518-523.	1.7	208
85	Improvement of Dry Mouth by Replacing Paroxetine with Fluvoxamine. Annals of Pharmacotherapy, 2005, 39, 567-571.	0.9	6
86	Functional characterization of human monocarboxylate transporter 6 (SLC16A5). Drug Metabolism and Disposition, 2005, 33, 1845-51.	1.7	67
87	Decreased Phenobarbital Absorption with Charcoal Administration for Chronic Renal Failure. Annals of Pharmacotherapy, 2004, 38, 73-76.	0.9	9
88	INHIBITORY EFFECTS OF POMELO ON THE METABOLISM OF TACROLIMUS AND THE ACTIVITIES OF CYP3A4 AND P-GLYCOPROTEIN. Drug Metabolism and Disposition, 2004, 32, 828-833.	1.7	52
89	Various Dosing Weights and Correction to Serum Digoxin Assays in Hemodialysis Patients. Journal of Pharmacy Technology, 2004, 20, 221-225.	0.5	1
90	Tolbutamide Uptake Via pH- and Membrane-potential-dependent Transport Mechanism in Mouse Brain Capillary Endothelial Cell Line. Drug Metabolism and Pharmacokinetics, 2004, 19, 270-279.	1.1	3

#	Article	IF	CITATIONS
91	Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. British Journal of Pharmacology, 2004, 143, 856-864.	2.7	132
92	Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. Transplantation Proceedings, 2004, 36, 1506-1511.	0.3	34
93	Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles. Pharmaceutical Research, 2003, 20, 38-44.	1.7	38
94	Basal Membrane Localization of MRP1 in Human Placental Trophoblast. Placenta, 2003, 24, 951-958.	0.7	113
95	Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharmaceutics and Drug Disposition, 2003, 24, 105-114.	1.1	24
96	In Vivo Delivery of Glial Cell-Derived Neurotrophic Factor Across the Blood-Brain Barrier by Gene Transfer into Brain Capillary Endothelial Cells. Human Gene Therapy, 2003, 14, 1181-1191.	1.4	36
97	Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. Transplantation, 2003, 75, 1057.	0.5	51
98	H ⁺ -linked transport of salicylic acid, an NSAID, in the human trophoblast cell line BeWo. American Journal of Physiology - Cell Physiology, 2002, 282, C1064-C1075.	2.1	64
99	Nightmares and Panic Disorder Associated with Carvedilol Overdose. Annals of Pharmacotherapy, 2002, 36, 1736-1740.	0.9	15
100	Transluminal Gene Transfer into Brain Capillary Endothelial Cells In Vivo with HVJ-liposomes. Journal of Drug Targeting, 2002, 10, 345-352.	2.1	13
101	Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochemical and Biophysical Research Communications, 2002, 296, 644-650.	1.0	25
102	Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Letters, 2002, 177, 89-93.	3.2	54
103	Characteristics of <scp>l</scp> -lactic acid transport in basal membrane vesicles of human placental syncytiotrophoblast. American Journal of Physiology - Cell Physiology, 2002, 283, C822-C830.	2.1	25
104	Transport and uptake of nateglinide in Caco-2 cells and its inhibitory effect on human monocarboxylate transporter MCT1. British Journal of Pharmacology, 2002, 137, 391-399.	2.7	52
105	Proton gradient-dependent transport of valproic acid in human placental brush-border membrane vesicles. Pharmaceutical Research, 2002, 19, 154-161.	1.7	26
106	Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharmaceutical Research, 2002, 19, 802-809.	1.7	93
107	Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein*. Clinical Pharmacology and Therapeutics, 2002, 72, 209-219.	2.3	275
108	Assessment of Systemic Adverse Reactions Induced by Ophthalmic β-Adrenergic Receptor Antagonists. Journal of Ocular Pharmacology and Therapeutics, 2001, 17, 235-248.	0.6	26

#	Article	IF	CITATIONS
109	Pharmacokinetic and Pharmacodynamic Analysis of the Antihypercalcemic Effect of Incadronate Disodium in Rats Biological and Pharmaceutical Bulletin, 2001, 24, 1290-1293.	0.6	1
110	A Comparative Pharmacodynamic Study of the Arrhythmogenicity of Antidepressants, Fluvoxamine and Imipramine, in Guinea Pigs Biological and Pharmaceutical Bulletin, 2001, 24, 550-554.	0.6	12
111	Transcellular transport of genistein, a soybean-derived isoflavone, across human colon carcinoma cell line (Caco-2). Biopharmaceutics and Drug Disposition, 2001, 22, 23-29.	1.1	28
112	Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect. Journal of Pharmacokinetics and Pharmacodynamics, 2001, 28, 533-554.	0.8	46
113	Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein. Journal of Controlled Release, 2001, 77, 77-86.	4.8	44
114	Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo). European Journal of Pharmacology, 2001, 417, 169-176.	1.7	21
115	Determination of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by high-performance liquid chromatography with amperometric detection. Biomedical Applications, 2000, 738, 405-411.	1.7	96
116	Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. British Journal of Pharmacology, 2000, 130, 1369-1377.	2.7	132
117	Effect of bioflavonoids on vincristine transport across blood–brain barrier. European Journal of Pharmacology, 2000, 395, 193-201.	1.7	136
118	Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. European Journal of Pharmacology, 2000, 408, 1-10.	1.7	128
119	Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice. Pharmaceutical Research, 2000, 17, 565-571.	1.7	24
120	Characteristics of choline transport across the blood-brain barrier in mice: correlation with in vitro data. Pharmaceutical Research, 2000, 17, 1526-1530.	1.7	32
121	Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1022-H1028.	1.5	76
122	Comparative Pharmacodynamic Analysis of Q-T Interval Prolongation Induced by the Macrolides Clarithromycin, Roxithromycin, and Azithromycin in Rats. Antimicrobial Agents and Chemotherapy, 2000, 44, 2630-2637.	1.4	66
123	Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Letters, 2000, 160, 21-28.	3.2	94
124	Induction of apoptosis in mouse brain capillary endothelial cells by cyclosporin a and tacrolimus. Life Sciences, 2000, 66, 2255-2260.	2.0	60
125	Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharmaceutics and Drug Disposition, 2000, 21, 129-138.	1.1	15
126	Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats. Journal of Pharmaceutical Sciences, 1999, 88, 234-240.	1.6	23

#	Article	IF	CITATIONS
127	Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. , 1999, 20, 101-106.		10
128	Sustained QT prolongation induced by tacrolimus in guinea pigs. Life Sciences, 1999, 65, PL197-PL202.	2.0	22
129	Pharmacokinetic/Pharmacodynamic Analysis of Tacrolimus-Induced QT Prolongation in Guinea Pigs Biological and Pharmaceutical Bulletin, 1999, 22, 1341-1346.	0.6	10
130	Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. Life Sciences, 1998, 62, 2159-2169.	2.0	11
131	Determination of erythromycin concentrations in rat plasma and liver by high-performance liquid chromatography with amperometric detection. Biomedical Applications, 1997, 692, 478-482.	1.7	18
132	Pharmacokinetic-Pharmacodynamic Analysis of the Electrocardiographic Effects of Terfenadine and Quinidine in Rats Biological and Pharmaceutical Bulletin, 1996, 19, 1189-1196.	0.6	19
133	Lack of Potentiation with Felbinac Patch on the Convulsive Toxicity of Enoxacin in Rats Biological and Pharmaceutical Bulletin, 1996, 19, 995-997.	0.6	0
134	Quantitative determination of epinastine in plasma by high-performance liquid chromatography. Biomedical Applications, 1996, 683, 281-284.	1.7	11
135	Antibronchospasmic, tachycardiac, and hypokalaemic effects of L-isoproterenol in guinea-pigs. Biopharmaceutics and Drug Disposition, 1995, 16, 745-753.	1.1	3
136	Prediction of the therapeutic dose for β-stimulants based on preclinical data: Application of oral dosage forms and aerosols to asthmatic patients. Journal of Pharmacokinetics and Pharmacodynamics, 1993, 21, 133-144.	0.6	2